CAR-T cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed advanced or metastatic solid tumor that has not responded to standard treatments or you cannot tolerate those treatments.
- Your tumor must test positive for a specific target protein (checked by the study team).
- You have at least one measurable tumor lesion on scans.
- You are in generally good health (able to do daily activities, expected to live at least 3 months).
- You have adequate organ function (blood counts, liver, kidney) and no serious heart or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.